
23 Feb Caribou Biosciences
Tim Kelly, Chief Technology Officer
Oct. 8 | 4:30pm | FLW Ballroom G
Berkeley, CA
(NASDAQ: CRBU)
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases.